Testing HEC585 tablets for idiopathic pulmonary fibrosis
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests a new tablet, HEC585, for people with idiopathic pulmonary fibrosis (IPF). It aims to see if the drug can help improve lung function and slow the disease. Participants must have a confirmed IPF diagnosis and meet specific breathing test results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 80 years old.
- You have been diagnosed with idiopathic pulmonary fibrosis (IPF) and it has been confirmed by a central review of your CT scan or lung biopsy.
- Your lung function tests show a forced expiratory volume (FEV1) to forced vital capacity (FVC) ratio of at least 0.7.
- Your FVC is at least 45% of the normal predicted value for someone of your age and height.
- Your diffusion capacity for carbon monoxide (DLco) is at least 30% of the normal predicted value.
- You are willing to use effective birth control if you or your partner could become pregnant, and you avoid donating sperm or eggs from the start of the trial until 30 days after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called AK3280 to see if it can help people with idiopathic pulmonary fibrosis (a lung disease that causes scarring). It aims to slow down the worsening of lung function. If you have IPF and haven't been treated with anti-fibrotic drugs recently, you might be able to join.
This trial tests a new drug called TDI01 to see if it helps people with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring. You may qualify if you have a confirmed IPF diagnosis and your lung function is stable enough.
This trial is testing a new medication called HSK50042 to see if it can help people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. If you have IPF and meet some basic health criteria, you might be able to join.
This Phase 2 study tests whether an oral medication (INS018_055) can help people with idiopathic pulmonary fibrosis (IPF). You may be a fit if your lung function is in a certain range and your condition is stable.
This trial tests a new drug called BC006 for people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. The goal is to see if it can help improve lung function. You may be eligible if you are 40 or older and have a confirmed IPF diagnosis with specific lung test results.
This study is testing a new investigational drug called HW241045 in healthy volunteers. The main goal is to check how the drug is processed by the body and whether it is safe, which helps find the right dose for future studies.
Hear when a new Idiopathic Pulmonary Fibrosis (IPF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.